Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Feb 19, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring the use of a special imaging technique called Al18F-octreotide PET/CT to help better understand and diagnose neuroendocrine tumors. Neuroendocrine tumors are a type of cancer that can develop in various parts of the body and may not always show clear symptoms. The trial aims to see how effective this imaging method is in identifying these tumors in patients who either have a confirmed diagnosis or are suspected of having one.

To participate in this study, individuals must be between the ages of 65 and 74 and have either a suspected or diagnosed neuroendocrine tumor. They also need to provide written consent and be willing to follow the study's requirements. However, pregnant or breastfeeding women, as well as those with certain medical conditions that might complicate their participation, cannot take part in the trial. Participants can expect to undergo imaging scans, and their involvement could contribute to improving how these tumors are diagnosed in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with suspected or clearly diagnosed Neuroendocrine Tumor
• • signed written consent.
• • Willing and able to cooperate with all projects in this study.
• Exclusion Criteria:
• • pregnancy;
• • breastfeeding;
• • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.